NCT04778124

Brief Summary

A wide variety of methods has been proposed for treating hemorrhoidal disease with excisional hemorrhoidectomy remaining the gold standard. The aim of this trial is to assess the safety and effectiveness of the HAL-RAR technique in treating hemorrhoidal disease. Arterial ligation was performed by using the highest doppler signal to locate the site of the hemorrhoidal artery in combination with RAR in order to reposition redundant rectal mucosa/submucosa that prolapses to its original anatomical location, leading to resolution of symptoms. This is a retrospective study from January 2010 to November 2019 of patients who underwent HAL-RAR for hemorrhoidal disease. Demographics, degree of disease, length of hospital stay, postoperative pain, complications (urinary retention, dyschezia, bleeding, necrosis of a hemorrhoid, anal discomfort, sensation of fullness) and recurrence were recorded. Patients were followed-up at postoperative day 1 and 8, and at 1, 6 and 12 months. The main outcome of the study was recurrence. Secondary outcomes included postoperative complications, postoperative pain and patient-assessed resolution of symptoms.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
105

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2010

Longer than P75 for not_applicable

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2010

Completed
9.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2019

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

February 25, 2021

Completed
5 days until next milestone

First Posted

Study publicly available on registry

March 2, 2021

Completed
Last Updated

March 2, 2021

Status Verified

February 1, 2021

Enrollment Period

9.8 years

First QC Date

February 25, 2021

Last Update Submit

February 26, 2021

Conditions

Keywords

hemorrhoidal diseasetreatmentHALRARmucopexy

Outcome Measures

Primary Outcomes (3)

  • Recurrence

    Recurrence was evaluated after physical examination and defined as a relapse of symptoms such as bleeding or prolapse often daily requiring manual reduction.

    Postoperatively at 1 month

  • Recurrence

    Recurrence was evaluated after physical examination and defined as a relapse of symptoms such as bleeding or prolapse often daily requiring manual reduction.

    Postoperatively at 6 months

  • Recurrence

    Recurrence was evaluated after physical examination and defined as a relapse of symptoms such as bleeding or prolapse often daily requiring manual reduction.

    Postoperatively at 12 months

Secondary Outcomes (11)

  • Postoperative complications

    Postoperative day 1

  • Postoperative complications

    Postoperative day 8

  • Postoperative complications

    Postoperatively at 1 month

  • Postoperative pain

    Postoperative day 1

  • Postoperative pain

    Postoperative day 8

  • +6 more secondary outcomes

Study Arms (1)

Patients with hemorrhoidal disease undergoing HAL-RAR

OTHER

This is a single-arm trial, in which all patients with grade II hemorrhoidal disease resistant to conservative treatment, grade III and IV hemorrhoidal disease underwent HAL RAR surgery.

Procedure: Hemorrhoidal Arterial Ligation (HAL) and Recto Anal Repair (RAR)Procedure: Excision of thrombosed hemorrhoid / Hemorrhoidectomy /

Interventions

All patients underwent hemorrhoidal artery ligation on multiple sites according to pulsations detected by the doppler transducer and mucopexy (RAR) at the sites of prolapse.

Patients with hemorrhoidal disease undergoing HAL-RAR

One patient with mucosal necrosis of the hemorrhoidal cushion postoperatively underwent hemorrhoidectomy with excision of necrotic tissues.Furthermore, 2 patients who presented with hemorrhoidal thrombosis postoperatively underwent emergency surgery with supplementary excision of the thrombosed hemorrhoid. In addition, 9 patients who experienced recurrence of hemorrhoidal disease after undergoing HAL-RAR surgery, were treated with hemorrhoidectomy according to the Milligan-Morgan procedure.

Patients with hemorrhoidal disease undergoing HAL-RAR

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with
  • grade II hemorrhoidal disease, resistant to conservative treatment
  • grade III hemorrhoidal disease,
  • grade IV hemorhoidal disease,
  • that underwent the HAL-RAR technique.

You may not qualify if:

  • pregnancy
  • coagulation disorders
  • patients with major comorbidities (American Society of Anesthesiologists \[ASA\] ≥3),
  • psychiatric conditions preventing collaboration and follow-up
  • other concomitant anorectal disease (rectal prolapse, anal fissure, anal stenosis, perianal fistula or abscess, fecal incontinence)
  • previous pelvic radiotherapy
  • declined consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (7)

  • Morinaga K, Hasuda K, Ikeda T. A novel therapy for internal hemorrhoids: ligation of the hemorrhoidal artery with a newly devised instrument (Moricorn) in conjunction with a Doppler flowmeter. Am J Gastroenterol. 1995 Apr;90(4):610-3.

    PMID: 7717320BACKGROUND
  • Ratto C, Campenni P, Papeo F, Donisi L, Litta F, Parello A. Transanal hemorrhoidal dearterialization (THD) for hemorrhoidal disease: a single-center study on 1000 consecutive cases and a review of the literature. Tech Coloproctol. 2017 Dec;21(12):953-962. doi: 10.1007/s10151-017-1726-5. Epub 2017 Nov 24.

    PMID: 29170839BACKGROUND
  • Popov V, Yonkov A, Arabadzhieva E, Zhivkov E, Bonev S, Bulanov D, Tasev V, Korukov G, Simonova L, Kandilarov N, Taseva A, Dimitrova V. Doppler-guided transanal hemorrhoidal dearterilization versus conventional hemorrhoidectomy for treatment of hemorrhoids - early and long-term postoperative results. BMC Surg. 2019 Jan 10;19(1):4. doi: 10.1186/s12893-019-0469-9.

    PMID: 30630463BACKGROUND
  • Aigner F, Gruber H, Conrad F, Eder J, Wedel T, Zelger B, Engelhardt V, Lametschwandtner A, Wienert V, Bohler U, Margreiter R, Fritsch H. Revised morphology and hemodynamics of the anorectal vascular plexus: impact on the course of hemorrhoidal disease. Int J Colorectal Dis. 2009 Jan;24(1):105-13. doi: 10.1007/s00384-008-0572-3. Epub 2008 Sep 3.

    PMID: 18766355BACKGROUND
  • Gallo G, Martellucci J, Sturiale A, Clerico G, Milito G, Marino F, Cocorullo G, Giordano P, Mistrangelo M, Trompetto M. Consensus statement of the Italian society of colorectal surgery (SICCR): management and treatment of hemorrhoidal disease. Tech Coloproctol. 2020 Feb;24(2):145-164. doi: 10.1007/s10151-020-02149-1. Epub 2020 Jan 28.

    PMID: 31993837BACKGROUND
  • Emile SH, Elfeki H, Sakr A, Shalaby M. Transanal hemorrhoidal dearterialization (THD) versus stapled hemorrhoidopexy (SH) in treatment of internal hemorrhoids: a systematic review and meta-analysis of randomized clinical trials. Int J Colorectal Dis. 2019 Jan;34(1):1-11. doi: 10.1007/s00384-018-3187-3. Epub 2018 Nov 12.

    PMID: 30421308BACKGROUND
  • Karkalemis K, Chalkias PL, Kasouli A, Chatzaki E, Papanikolaou S, Dedemadi G. Safety and effectiveness of hemorrhoidal artery ligation using the HAL-RAR technique for hemorrhoidal disease. Langenbecks Arch Surg. 2021 Nov;406(7):2489-2495. doi: 10.1007/s00423-021-02190-0. Epub 2021 May 6.

MeSH Terms

Interventions

Hemorrhoidectomy

Intervention Hierarchy (Ancestors)

Digestive System Surgical ProceduresSurgical Procedures, Operative

Study Officials

  • Georgia Dedemadi, MD, PhD

    Amalia Fleming Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD, PhD, FACS

Study Record Dates

First Submitted

February 25, 2021

First Posted

March 2, 2021

Study Start

January 1, 2010

Primary Completion

November 1, 2019

Study Completion

November 1, 2019

Last Updated

March 2, 2021

Record last verified: 2021-02

Data Sharing

IPD Sharing
Will not share